NCT05702450View on ClinicalTrials.gov

Study to Evaluate Pharmacokinetics, Safety and Efficacy of CM310

PHASE1CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

March 22, 2023

Primary Completion Date

July 26, 2023

Study Completion Date

July 26, 2023

Conditions
Healthy
Interventions
BIOLOGICAL

CM310

CM310 Recombinant Humanized Monoclonal Antibody Injection

Trial Locations (1)

Unknown

PKUCare Luzhong Hospital, Zibo

Sponsors
All Listed Sponsors
lead

Keymed Biosciences Co.Ltd

INDUSTRY

NCT05702450 - Study to Evaluate Pharmacokinetics, Safety and Efficacy of CM310 | Biotech Hunter | Biotech Hunter